Figen DOĞU, Aydan İKİNCİOĞULLARI, Emel BABACAN, Deniz GÜLOĞLU, Mutu YÜKSEK, Alişan YILDIRAN, Funda Erol ÇİPE

Serum transforming growth factor-beta(TGF-beta), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9 ) and tissue inhibitors of metalloproteinase (TIMP-1) levels in childhood asthma

Amaç: Hava yollarında yeniden yapılanma (remodelling) ekstraselüler matriksin yapım ve yıkımını içeren dinamik bir süreçtir ve astımın karakteristik özelliğidir. Matriks metalloproteinazları(MMP) ve metalloproteinazların doku inhibitörleri olarak bilinen spesifik inhibitörleri (TIMP) bu süreçte önemli rol oynarlar. Bu çalışmada stabil astımlı çocuklarda ve sağlıklı kontrollerde serum TGF-B,MMP-2, MMP-9 ve TIMP-1 düzeylerini ölçerek bu belirteçlerin astımlı ve sağlıklı çocuklarda farklı olup olmadığının ve atopi varlığından etkilenip etkilenmediğinin belirlenmesi amaçlandı. Yöntem ve Gereç: Polikliniğimizde tanı alan ve izlenen yaşları 6-16 arasında değişen 31 stabil astımlı olgu (16 atopik, 15 nonatopik) ve benzer yaş grubundan 13 sağlıklı gönüllü çocuk çalışmaya alındı. Serum TGF- β,MMP-2, MMP-9 ve TIMP-1 düzeyleri ELISA yöntemi ile ölçüldü. Bulgular: Hastalar ve kontroller arasında TGF-β,MMP-2, ve TIMP-1 düzeyleri açısından fark bulunmazken, serum MMP-9 düzeyleri astımlı çocuklarda sağlıklı çocuklara göre belirgin yüksek bulundu. Atopik ve nonatopik astımlılar arasında TGF-β, MMP-2, MMP-9 ve TIMP-1 düzeyleri açısından farklılık saptanmadı. Sonuç: Bu çalışmanın sonuçları astım patogenezinde MMP’lerin özellikle MMP-9’un rol oynadığı yönünde kanıtları desteklemektedir. MMP-9 düzeyleri çocukluk çağı astımında en önemli risk faktörlerinden olan atopiden ise etkilememektedir.

Astımlı çocuklarda serum transforming growth factor-beta(TGF-beta), matrix metalloproteinaz-2 (MMP-2), matriks metalloproteinaz-9 (MMP-9) ve metalloproteinaz doku inhibitörü-1 (TIMP-1) Düzeyleri

Aims: Airway remodelling is a characteristic feature of asthma and is a dynamic process involving extracellular matrix (ECM) production and its degradation. In this regard, the matrix metalloproteinases (MMPs) and their specific inhibitors known as tissue inhibitors of metalloproteinases (TIMPs) have been shown to be important in this process. In the present study, transforming growth factor (TGF)-β, MMP-2, MMP-9 and TIMP-1 levels in serum samples of children with stable asthma and healthy controls were evaluated to determine whether these levels show any difference between asthmatic and healthy children and whether or not these levels change with atopic status. Materials and Methods: Thirty-one mild to moderate stable asthmatic children aged 6-16 years (16 atopic, 15 non-atopic) who were followed in our clinic and 13 age-matched healthy volunteers were enrolled in the study. Serum TGF-β, MMP-2, MMP-9 and TIMP-1 levels were measured by ELISA. Results: There were no significant differences in serum levels of TGF-β, MMP-2 and TIMP-1 between patients and controls. However, serum MMP-9 levels of asthmatic children were found to be significantly higher than those of healthy controls. No difference was observed between atopic and non-atopic asthmatics for TGF-β, MMP-2, MMP-9 and TIMP-1 levels. Conclusions: Results of the present study support the evidence regarding the involvement of MMPs, especially MMP-9, in the asthma pathogenesis. However, MMP-9 levels do not seem to be influenced by atopic status, which is the most significant risk factor in childhood asthma.

PDF

___

1. Pohunek P. Pediatric asthma: how significant it is for the whole life? Paediatr Respir Rev 2006; 7(Suppl): s68-s69.
2. Guilbert TW, Morgan WJ, Zeiger RS, Bacharier LB, Boehmer SJ, Krawiec M et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol 2004; 114: 1282-7.
3. http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=49
4. Lee YC, Lee HB, Rhee YK, Song CH. The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy 2001; 31: 1623-30.
5. Matsumoto H, Niimi A, Takemura M, Ueda T, Minakuchi M, Tabuena R et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005; 60: 277-81.
6. Xu J, Benyon C, Leir SH, Zhang S, Holgate ST, Lackie PM et al. Matrix metalloproteinase-2 from bronchial epithelial cells induces the proliferation of subepithelial fibroblasts. Clin Exp Allergy 2002; 32: 881-8.
7. Tang LF, Du LZ, Chen ZM, Zou CC. Levels of matrix metalloproteinase-9 and its inhibitor in bronchoalveolar lavage cells of asthmatic children. Fetal Pediatr Pathol 2006; 25: 1-7.
8. Gueders MM, Foidart JM, Noel A, Cataldo DD. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 2006; 533: 133-44.
9. Doherty GM, Kamath FC, Christie SN, Chisakuta A, Lyons JD, Heaney LG et al. Children with stable asthma have reduced airway matrix metalloproteinase-9 and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio. Clin Exp Allergy 2005; 35:1168-74.
10. Belleguic C, Corbel M, Germain N, Léna H, Boichot E, Delaval PH et al. Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin Exp Allergy 2002;31: 217-23.
11. Barbato A. Turato G, Baraldo S, Bazzan E, Calabrese F, Tura M et al. Airway inflammation in childhood asthma. Am J Respir Crit Care Med 2003; 168: 798-803.
12. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003;349(15): 1414-22.
13. Martinez FD. Toward asthma prevention-does all that really matters happen before we learn to read? N Engl J Med 2003;349: 1473-5.
14. Hoshino M, Takahashi M, Takai Y, Sim J. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999; 104: 356-63.